News | October 04, 2011

Experts Urge FDA to Remove Echo Contrast Box Warnings

October 4, 2011 – The International Contrast Ultrasound Society (ICUS) submitted a petition this week to the U.S. Food and Drug Administration (FDA) requesting removal of the boxed warnings on ultrasound contrast agents. The members of the group say this would bring the product labeling into line with the current body of scientific research, which it says clearly demonstrates the safety and clinical benefits of these imaging products.

ICUS members are concerned that current boxed warnings may unduly deter the use of an exceedingly safe, reliable, non-invasive and cost-effective diagnostic imaging tool that does not expose patients to ionizing radiation. Given the potential life-saving benefits of ultrasound contrast agents and the potential risks associated with their non-use, ICUS believes the warnings are inconsistent with the standards of the FDA for use of boxed warnings. ICUS said at the time the FDA required the boxed warnings, there may have been insufficient data to support clinicians’ positive experience with ultrasound contrast agents. They added that the FDA’s decision to add boxed warnings was, at that time, consistent with its regulatory authority and guidance.

However, ICUS contends the threshold criteria used by the FDA to determine whether a particular medication should be assigned a box warning clearly no longer apply to echo ultrasound contrast agents. When assessing the risks and benefits, ICUS said the adverse reaction rate is not serious enough in proportion to the potential benefit of the drug.

The group said ultrasound contrast agents should be encouraged for a number of important reasons, including their safety, improvement to diagnostic accuracy, their use encourages reduced exposure to ionizing radiation, and they reduce overall healthcare cost. ICUS said the boxed warnings deter use of ultrasound contrast agents, especially in critically ill patients who have the most to gain from a more reliable diagnosis and expeditiously administered therapies.

The safety of ultrasound contrast agents has been extensively studied since the FDA decision to require boxed warnings on the product labels. In addition to six safety studies undertaken by the product sponsors, numerous independent investigator-initiated scientific studies have now been published in peer-reviewed medical and scientific journals, showing no increased safety signal even among the sickest patients. ICUS contends these studies show ultrasound contrast agents are not associated with increased risk of death, myocardial infarction or other morbidities. The group said the studies also show the agents are safe in patients with pulmonary hypertension, acute myocardial infarction and congestive heart failure, in critically ill patients in the intensive care unit, and in patients undergoing stress testing.

By way of example, a recent meta-analyses of these studies showed the risk of death for contrast echocardiography was 0.34 percent (726 out of 211,162 patients) versus 0.9 percent in patients undergoing unenhanced echocardiography (45 out of 5 million patients).                 

In studying more than 4.3 million patients, it was found that those receiving a contrast agent were actually 24 percent less likely to die within 24 hours than patients who did not receive a contrast agent during an ultrasound diagnostic examination, ICUS wrote in its petition.

Similarly, the American Society of Echocardiography Multi-Center Registry of thirteen sites and more than 66,000 doses showed (a) no deaths, (b) no serious adverse events in hospitalized patients, (c) severe adverse reactions in eight non-hospitalized patients (0.01 percent), and (d) anaphylactoid reactions (severe allergic reactions) in four patients (0.006 percent). The authors of the study concluded the incidence of severe adverse reactions to ultrasound contrast agents is lower than, or similar to, that reported for contrast agents commonly used in other cardiac imaging tests. Further, a meta-analysis of eight controlled observational registry studies, with nearly a quarter million patients, concluded: “the cumulative evidence has suggested that the use of contrast agents for echocardiography is safe." In fact, the meta-analysis actually showed lower mortality rates in patients who received ultrasound contrast recipients. According to the senior author, "we did not see any signal that echo contrast was causing any harm."

ICUS said, as with any medical procedure or device, ultrasound contrast agents do carry some associated risks. The most serious is the potential for an anaphylactoid reaction. However, studies have shown that the risk of an anaphylactic reaction from an ultrasound contrast agent is comparable to that of non-ultrasound contrast agents — approximately 1 in 10,000 events. In addition, according to the data from the American Society of Echocardiography Multi-Center Registry, the incidence of severe adverse reactions to ultrasound contrast agents is lower than, or similar to, that reported for contrast agents commonly used for other cardiac imaging. ICUS said these studies have shown that the majority (65 percent) of patients who experienced an adverse event had a history of allergy.

For more information:  www.icus-society.org 

Related Content

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
Overlay Init